- cafead   Aug 30, 2023 at 11:12: AM
via The FDA on Wednesday rejected Outlook Therapeutics’ investigational ophthalmic bevacizumab solution ONS-5010, which the company was proposing as a treatment for wet age-related macular degeneration.
article source
article source